原发性肾上腺皮质功能不全:盐皮质激素替代治疗的管理
该综述系统检索1939至2017年文献,回顾原发性肾上腺皮质功能不全患者盐皮质激素替代治疗的现行标准及可能影响。现行标准为氟氢可的松每日晨服一次,目标是血压正常、血钾正常及血浆肾素活性处于正常上限。现有数据提示部分患者可能存在盐皮质激素替代不足。
要点
- 现行标准盐皮质激素替代为氟氢可的松每日晨服一次。
- 治疗目标为血压正常、血钾正常及血浆肾素活性处于正常上限。
- 部分患者可能盐皮质激素替代不足,与不良心脏代谢结局相关。
核心结论
- 常用盐皮质激素替代在某些原发性肾上腺皮质功能不全患者中可能不充分。
- 盐皮质激素替代不足可能导致不良心脏代谢结局及未能充分恢复健康状态。
- 亟需精心设计的研究以优化盐皮质激素替代治疗。
研究设计与样本
- 使用PubMed对1939至2017年文献进行系统综述,关键词包括肾上腺皮质功能不全、盐皮质激素缺乏、醛固酮、心血管疾病、高血压和心力衰竭。
主要发现
- 现行标准治疗为氟氢可的松每日晨服一次,目标为血压正常、血钾正常及血浆肾素活性处于正常上限。
- 现有数据提示许多接受治疗的原发性肾上腺皮质功能不全患者仍存在盐渴望和体位性头晕等慢性盐皮质激素替代不足的症状和体征。
- 来自大型登记研究的数据显示,原发性肾上腺皮质功能不全的糖皮质激素替代剂量高于内源性生成估计量。
- 糖皮质激素替代过量可能减少盐皮质激素替代需求,但也可能是不充分盐皮质激素替代的结果。
关键数值与推荐
- 现行标准盐皮质激素替代为氟氢可的松每日晨服一次。
- 治疗目标为血压正常、血钾正常及血浆肾素活性处于正常上限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 盐皮质激素剂量方案仅在少数研究中被系统研究。
- 亟需精心设计的研究以优化盐皮质激素替代治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Mineralocorticoid (MC) replacement therapy in patients with primary adrenal insufficiency (PAI) was introduced more than 60 years ago. Still, there are limited data on how MC substitution should be optimized, because MC dosing regimens have only been systematically investigated in a few studies. We review the management of current standard MC replacement therapy in PAI and its plausible impact on outcome. DESIGN: Using PubMed, we conducted a systematic review of the literature from 1939 to 2017, with the following keywords: adrenal insufficiency, MC deficiency, aldosterone, cardiovascular disease, hypertension, and heart failure. RESULTS: The current standard treatment consists of fludrocortisone (FC) given once daily in the morning, aiming at normotension, normokalemia, and plasma renin activity in the upper normal range. Available data suggest that patients with PAI may be underreplaced with FC as symptoms and signs indicating chronic MC underreplacement, such as salt craving and postural dizziness persist, in many treated patients with PAI. Data acquired from large registry-based studies show that glucocorticoid doses for replacement in PAI are higher than those estimated from endogenous production. Glucocorticoid overreplacement may reduce the need of MC replacement but may also be a consequence of inadequate MC replacement. CONCLUSIONS: The commonly used MC replacement in PAI may not be adequate in some patients. Insufficient MC substitution may be responsible for poor cardiometabolic outcome and the failure to restore well-being adequately in patients with PAI. Well-designed studies oriented at optimizing MC replacement therapy are urgently needed.
引用
- Esposito D, Pasquali D, Johannsson G, et al. Primary Adrenal Insufficiency: Managing Mineralocorticoid Replacement Therapy. J Clin Endocrinol Metab. 2018. PMID: 29156052. doi:10.1210/jc.2017-01928
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。